secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0000950170-24-129402
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics prices $30M registered direct offering at $0.76/unit with warrants
--------------------------------------------------------------------------------

- Combined purchase price of $0.76 per share and warrant; $24M from institutional investors, $6M from Broadwood affiliate.
- Warrants exercisable at $0.91 for up to ~39.5M shares; expire 3 years from exercise date or 90 days post OpRegen milestone.
- Broadwood portion requires shareholder approval under NYSE American rules; closing contingent on satisfaction of conditions.
- Net proceeds to fund working capital, R&D, and capital expenditures; potential additional $36M if warrants exercised.
- H.C. Wainwright serves as exclusive placement agent with 7% cash fee and 5% warrant coverage at $0.95 exercise price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024129402/0000950170-24-129402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024129402/lctx-20241119.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer